{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:15:03Z","timestamp":1781658903524,"version":"3.54.5"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GGP12108"],"award-info":[{"award-number":["GGP12108"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GGP12108"],"award-info":[{"award-number":["GGP12108"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007801","name":"Fundaci\u00f3n S\u00e9neca","doi-asserted-by":"publisher","award":["18946\/JLI\/13"],"award-info":[{"award-number":["18946\/JLI\/13"]}],"id":[{"id":"10.13039\/100007801","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NLHPC","award":["ECM-02"],"award-info":[{"award-number":["ECM-02"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0165463","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T17:49:54Z","timestamp":1477590594000},"page":"e0165463","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease"],"prefix":"10.1371","volume":"11","author":[{"given":"Valentina","family":"Citro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Pe\u00f1a-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"den-Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"P\u00e9rez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosita","family":"Del Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cimmaruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-6553","authenticated-orcid":true,"given":"Maria Vittoria","family":"Cubellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1007\/8904_2015_435","article-title":"The Frequencies of Different Inborn Errors of Metabolism in Adult Metabolic Centres: Report from the SSIEM Adult Metabolic Physicians Group","author":"S Sirrs","year":"2015","journal-title":"JIMD Rep"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"DP Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis","volume":"3","author":"M Beck","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-1172-8-29","article-title":"Cost-effectiveness of enzyme replacement therapy for Fabry disease","volume":"8","author":"SM Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/humu.22910","article-title":"Functional and Clinical Consequences of Novel alpha-Galactosidase A Mutations in Fabry Disease","volume":"37","author":"J Lukas","year":"2016","journal-title":"Hum Mutat"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"JQ Fan","year":"1999","journal-title":"Nat Med"},{"issue":"9","key":"ref7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/FPC.0b013e32830500f4","article-title":"Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone","volume":"18","author":"SH Shin","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/humu.9520","article-title":"Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone","volume":"29","author":"M Shimotori","year":"2008","journal-title":"Hum Mutat"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3858\/emm.2009.41.1.001","article-title":"Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease","volume":"41","author":"JY Park","year":"2009","journal-title":"Exp Mol Med"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"ER Benjamin","year":"2009","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of alpha-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"X Wu","year":"2011","journal-title":"Hum Mutat"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease","volume":"9","author":"J Lukas","year":"2013","journal-title":"PLoS Genet"},{"key":"ref13","article-title":"Functional and Clinical Consequences of Novel alpha-Galactosidase A Mutations in Fabry Disease","author":"J Lukas","year":"2015","journal-title":"Hum Mutat"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/jpet.108.149054","article-title":"Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease","volume":"328","author":"S Ishii","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"R Khanna","year":"2010","journal-title":"Febs J"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"DP Germain","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","article-title":"A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects","volume":"109","author":"R Giugliani","year":"2013","journal-title":"Mol Genet Metab"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2011.01.013","article-title":"Molecular mechanism for stabilization of a mutant alpha-galactosidase A involving M51I amino acid substitution by imino sugars","volume":"103","author":"T Tsukimura","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"15","key":"ref19","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1021\/ol201552q","article-title":"Looking-glass synergistic pharmacological chaperones: DGJ and L-DGJ from the enantiomers of tagatose","volume":"13","author":"SF Jenkinson","year":"2011","journal-title":"Org Lett"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/cb500143h","article-title":"Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human alpha-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants","volume":"9","author":"Y Yu","year":"2014","journal-title":"ACS Chem Biol"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/mt.2014.224","article-title":"Enzyme enhancers for the treatment of fabry and pompe disease","volume":"23","author":"J Lukas","year":"2015","journal-title":"Mol Ther"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"I Bendikov-Bar","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/ci049714+","article-title":"ZINC\u2014a free database of commercially available compounds for virtual screening","volume":"45","author":"JJ Irwin","year":"2005","journal-title":"J Chem Inf Model"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.taap.2012.06.010","article-title":"2,6-Dithiopurine, a nucleophilic scavenger, protects against mutagenesis in mouse skin treated in vivo with 2-(chloroethyl) ethyl sulfide, a mustard gas analog","volume":"263","author":"S Boulware","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1021\/tx9001918","article-title":"2,6-Dithiopurine blocks toxicity and mutagenesis in human skin cells exposed to sulfur mustard analogues, 2-chloroethyl ethyl sulfide and 2-chloroethyl methyl sulfide","volume":"23","author":"KL Powell","year":"2010","journal-title":"Chem Res Toxicol"},{"issue":"8","key":"ref26","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0090-9556(25)06668-1","article-title":"Toxicity and metabolism in mice of 2,6-dithiopurine, a potential chemopreventive agent","volume":"23","author":"WG Qing","year":"1995","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","article-title":"The molecular basis of pharmacological chaperoning in human alpha-galactosidase","volume":"18","author":"AI Guce","year":"2011","journal-title":"Chem Biol"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1021\/ci800166p","article-title":"Lead finder: an approach to improve accuracy of protein-ligand docking, binding energy estimation, and virtual screening","volume":"48","author":"OV Stroganov","year":"2008","journal-title":"J Chem Inf Model"},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1021\/ci300601q","article-title":"Enhancing molecular shape comparison by weighted Gaussian functions","volume":"53","author":"X Yan","year":"2013","journal-title":"J Chem Inf Model"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/108705710100600609","article-title":"High-density miniaturized thermal shift assays as a general strategy for drug discovery","volume":"6","author":"MW Pantoliano","year":"2001","journal-title":"J Biomol Screen"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ab.2004.04.031","article-title":"Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery","volume":"332","author":"MC Lo","year":"2004","journal-title":"Anal Biochem"},{"key":"ref32","article-title":"Looking for protein stabilizing drugs with thermal shift assay","author":"G Andreotti","year":"2015","journal-title":"Drug Test Anal"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mgg3.3","article-title":"Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation","volume":"1","author":"G Andreotti","year":"2013","journal-title":"Mol Genet Genomic Med"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/pro.115","article-title":"Determining protein stability in cell lysates by pulse proteolysis and Western blotting","volume":"18","author":"MS Kim","year":"2009","journal-title":"Protein Sci"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.bbagen.2013.12.018","article-title":"A thermodynamic assay to test pharmacological chaperones for Fabry disease","volume":"1840","author":"G Andreotti","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1750-1172-6-66","article-title":"Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests","volume":"6","author":"G Andreotti","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"MM Bradford","year":"1976","journal-title":"Anal Biochem"},{"issue":"Web Server issue","key":"ref38","doi-asserted-by":"crossref","first-page":"W215","DOI":"10.1093\/nar\/gkr363","article-title":"SDM\u2014a server for predicting effects of mutations on protein stability and malfunction","volume":"39","author":"CL Worth","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/prot.20810","article-title":"Prediction of protein stability changes for single-site mutations using support vector machines","volume":"62","author":"J Cheng","year":"2006","journal-title":"Proteins"},{"issue":"Suppl 4","key":"ref40","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/1471-2105-6-S4-S8","article-title":"Secondary structure assignment that accurately reflects physical and evolutionary characteristics","volume":"6","author":"MV Cubellis","year":"2005","journal-title":"BMC Bioinformatics"},{"issue":"Suppl 7","key":"ref41","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1471-2105-14-S7-S9","article-title":"Identification and analysis of conserved pockets on protein surfaces","volume":"14","author":"M Cammisa","year":"2013","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/prot.20251","article-title":"Making optimal use of empirical energy functions: force-field parameterization in crystal space","volume":"57","author":"E Krieger","year":"2004","journal-title":"Proteins"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biochi.2015.03.018","article-title":"Taming molecular flexibility to tackle rare diseases","volume":"113","author":"MV Cubellis","year":"2015","journal-title":"Biochimie"},{"issue":"4","key":"ref44","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"IA Adzhubei","year":"2010","journal-title":"Nat Methods"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1750-1172-8-111","article-title":"Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones","volume":"8","author":"M Cammisa","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13023-015-0273-2","article-title":"Drug repositioning can accelerate discovery of pharmacological chaperones","volume":"10","author":"B Hay Mele","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"ref47","first-page":"227","article-title":"Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes","volume":"48","author":"P Ashton-Prolla","year":"2000","journal-title":"J Investig Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1172-5-36","article-title":"Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study","volume":"5","author":"G Andreotti","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"ref49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"S Ishii","year":"2007","journal-title":"Biochem J"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1006\/bbrc.1995.2416","article-title":"Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease","volume":"214","author":"T Okumiya","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"ref51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"M Spada","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"6","key":"ref52","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cbpa.2003.10.004","article-title":"Evolutionary markers in the (beta\/alpha)8-barrel fold","volume":"7","author":"MC Vega","year":"2003","journal-title":"Curr Opin Chem Biol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0165463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T21:59:43Z","timestamp":1749679183000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0165463"}},"subtitle":[],"editor":[{"given":"Stephan N.","family":"Witt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0165463","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]}}}